BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 8371711)

  • 1. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
    Mackie K; Devane WA; Hille B
    Mol Pharmacol; 1993 Sep; 44(3):498-503. PubMed ID: 8371711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
    Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.
    Mackie K; Hille B
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3825-9. PubMed ID: 1315042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of anandamide on cannabinoid receptors in rat brain membranes.
    Childers SR; Sexton T; Roy MB
    Biochem Pharmacol; 1994 Feb; 47(4):711-5. PubMed ID: 8129747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes.
    Sagan S; Venance L; Torrens Y; Cordier J; Glowinski J; Giaume C
    Eur J Neurosci; 1999 Feb; 11(2):691-9. PubMed ID: 10051770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
    Vogel Z; Barg J; Levy R; Saya D; Heldman E; Mechoulam R
    J Neurochem; 1993 Jul; 61(1):352-5. PubMed ID: 8515284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New dawn of cannabinoid pharmacology.
    Devane WA
    Trends Pharmacol Sci; 1994 Feb; 15(2):40-1. PubMed ID: 8165721
    [No Abstract]   [Full Text] [Related]  

  • 8. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons.
    Guo J; Ikeda SR
    Mol Pharmacol; 2004 Mar; 65(3):665-74. PubMed ID: 14978245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons.
    Twitchell W; Brown S; Mackie K
    J Neurophysiol; 1997 Jul; 78(1):43-50. PubMed ID: 9242259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of aminoalkylindoles to noncannabinoid binding sites in NG108-15 cells.
    Stark S; Pacheco MA; Childers SR
    Cell Mol Neurobiol; 1997 Oct; 17(5):483-93. PubMed ID: 9353590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain.
    Nicholson RA; Liao C; Zheng J; David LS; Coyne L; Errington AC; Singh G; Lees G
    Brain Res; 2003 Jul; 978(1-2):194-204. PubMed ID: 12834914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system.
    Pan X; Ikeda SR; Lewis DL
    Mol Pharmacol; 1996 Apr; 49(4):707-14. PubMed ID: 8609900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons.
    Huang CC; Lo SW; Hsu KS
    J Physiol; 2001 May; 532(Pt 3):731-48. PubMed ID: 11313442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices.
    Ameri A; Wilhelm A; Simmet T
    Br J Pharmacol; 1999 Apr; 126(8):1831-9. PubMed ID: 10372827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.
    Hampson AJ; Bornheim LM; Scanziani M; Yost CS; Gray AT; Hansen BM; Leonoudakis DJ; Bickler PE
    J Neurochem; 1998 Feb; 70(2):671-6. PubMed ID: 9453561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CB1 cannabinoid receptor-mediated cell migration.
    Song ZH; Zhong M
    J Pharmacol Exp Ther; 2000 Jul; 294(1):204-9. PubMed ID: 10871313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
    Slipetz DM; O'Neill GP; Favreau L; Dufresne C; Gallant M; Gareau Y; Guay D; Labelle M; Metters KM
    Mol Pharmacol; 1995 Aug; 48(2):352-61. PubMed ID: 7651369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system.
    McAllister SD; Griffin G; Satin LS; Abood ME
    J Pharmacol Exp Ther; 1999 Nov; 291(2):618-26. PubMed ID: 10525080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
    Pertwee RG; Stevenson LA; Griffin G
    Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma x glioma hybrid NG108-15 cells.
    Sugiura T; Kodaka T; Kondo S; Tonegawa T; Nakane S; Kishimoto S; Yamashita A; Waku K
    Biochem Biophys Res Commun; 1996 Dec; 229(1):58-64. PubMed ID: 8954083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.